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Background: Autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) have 
emerged as an independent biomarker for cardiovascular disease and mortality. 
However, their association with all-cause mortality in the community, as well as their 
genetic determinants, have not been studied.
Objective: To determine whether anti-apoA-1 IgG: (a) predict all-cause mortality in the 
general population and (b) are associated with single-nucleotide polymorphisms (SNPs) 
in a genome-wide association study (GWAS).
Methods: Clinical, biological, and genetic data were obtained from the population-based, 
prospective CoLaus study, including 5,220 participants (mean age 52.6 years, 47.3% 
men) followed over a median duration of 5.6 years. The primary study outcome was 
all-cause mortality.
results: After multivariate adjustment, anti-apoA-1 IgG positivity independently pre-
dicted all-cause mortality: hazard ratio (HR)  =  1.54, 95% confidence interval (95% 
CI): 1.11–2.13, P =  0.01. A dose–effect relationship was also observed, each SD of 
logarithmically transformed anti-apoA-1 IgG being associated with a 15% increase in 
mortality risk: HR = 1.15, 95% CI: 1.02–1.28, P = 0.028. The GWAS yielded nine SNPs 
belonging to the Fc receptor-like 3 (FCRL3) gene, which were significantly associated 
with anti-apoA-1 IgG levels, with the lead SNP (rs6427397, P = 1.54 × 10−9) explaining 
0.67% of anti-apoA-1 IgG level variation.
conclusion: Anti-apoA-1 IgG levels (a) independently predict all-cause mortality in 
the general population and (b) are linked to FCRL3, a susceptibility gene for numerous 
autoimmune diseases. Our findings indicate that preclinical autoimmunity to anti-apoA-1 
IgG may represent a novel mortality risk factor.
Keywords: autoimmunity, autoantibodies, apolipoprotein a-1, mortality, genome-wide association study, 
Fc receptor-like 3
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inTrODUcTiOn
Autoimmune diseases (ADs) represent a major health issue 
affecting up to 10% of the population (1–4). Multiple studies 
have established the relationship between a chronic inflamma-
tory state due to clinical or quiescent autoimmunity and poor 
outcomes in various clinical settings (5, 6). Marking sustained 
B-cell activation, presence of autoantibodies specifically rep-
resents a signature of humoral autoimmunity, which can drive 
disease pathogenesis even in the absence of overt clinical AD 
(7–9).
More than a decade ago, early clinical studies have sup-
ported the role of autoantibodies against apolipoprotein A-1 
(anti-apoA-1 IgG), the principal component of high-density 
lipoproteins (HDLs), as mediators of chronic low-grade inflam-
mation and predictors of unfavorable outcomes in patients 
with ADs (10–17). Subsequently, in  vitro and animal studies 
demonstrated the ability of these autoantibodies to elicit a pro-
inflammatory and pro-atherogenic response through interac-
tion with the TLR2/TLR4/CD14 complex, followed by NF-κB 
and MAPK downstream activation as the main molecular 
pathway (18–24).
Recently, due to these pro-inflammatory and pro-atherogenic 
properties, anti-apoA-1 IgG gained interest as independent 
biomarkers for incident cardiovascular (CV) disease (CVD) and 
mortality, as well as potential therapeutic targets for immune-
modulating interventions, in high CV risk populations (16, 19, 
20, 22, 25–28). Moreover, similar to what has been reported 
with other autoantibodies (7), our group recently demonstrated 
that elevated anti-apoA-1 IgG levels were present in up to 20% 
of individuals in the general population and associated with 
prevalent CVD independently of traditional CV risk factors 
(25). Nevertheless, the association of anti-apoA-1 IgG with 
all-cause mortality in the general population has not yet been 
studied.
From another point of view, while rare autoimmunity 
syndromes can result from monogenic mutations, common 
human ADs are complex disorders arising from the interaction 
between polygenic and environmental risk factors, disrupting 
mechanisms of immune tolerance. In recent years, genome-wide 
association studies (GWASs) have provided insight into the subtle 
immune dysregulation caused by common genetic variants that 
predispose to clinical autoimmunity (29, 30) and autoantibody 
production in particular (31–34).
Although the risk attributable to most of the identified 
individual nucleotide variants is modest, modern GWAS have 
the potential to provide an unbiased view of biological pathways 
that drive autoimmunity (1–4). However, despite the associations 
of anti-apoA-1 IgG with adverse outcomes in different patient 
populations, no study has so far investigated common genetic 
variants potentially related to their serum values.
Thus, the goal of the present study was twofold. We aimed to 
determine whether anti-apoA-1 IgG: (a) predict all-cause mortal-
ity in the general population in a prospective study and (b) are 
associated with single-nucleotide polymorphisms (SNPs) in a 
GWAS.
MeThODs
study Population and Design
Clinical and biological data were obtained from the CoLaus 
study, a population-based prospective cohort of 6,733 partici-
pants recruited between 2003 and 2006 in the city of Lausanne, 
Switzerland. Of the initial baseline sample of 6,733 participants, 
5,220 (mean age 52.6 ±  10.7  years, 47.3% men) had complete 
clinical and biological data over a median follow-up (FU) time 
of 5.6  years and were included in the prospective analysis. A 
detailed description of the study design, variables, and sampling 
procedures has been reported elsewhere (35).
All participants attended the outpatient clinic of the University 
Hospital of Lausanne. Clinical data and fasting venous blood 
samples were collected from each participant by trained field 
interviewers during a single visit lasting about 60  min. Blood 
pressure and heart rate were measured three consecutive times 
using an automated sphygmomanometer (Omron® HEM-907, 
Matsusaka, Japan), and the average of the last two measurements 
was used. Body weight and height were measured with partici-
pants standing without shoes in light indoor clothes. Body weight 
was measured in kilograms to the nearest 100  g using a Seca® 
scale, and height was measured to the nearest 5 mm using a Seca® 
height gauge. Body mass index (BMI) was calculated as weight 
(kg)/height (m2). Hypertension was defined as a systolic blood 
pressure ≥140 mm Hg and/or a diastolic blood pressure ≥90 mm 
Hg and/or the presence of anti-hypertensive treatment. Diabetes 
mellitus was defined as fasting plasma glucose ≥7.0 mmol/l and/
or oral or insulin anti-diabetic treatment. History of CVD was 
defined by the presence of myocardial infarction, angina pectoris, 
percutaneous revascularization or bypass grafting for ischemic 
heart disease, and stroke or transient ischemic attack and assessed 
according to standardized medical records (35). History of ADs 
was obtained via questionnaire. Estimated glomerular filtration 
rate (eGFR) was calculated by the simplified “Modification of Diet 
in Renal Disease” prediction equation. Absolute risk for CVD 
was computed using the Systematic Coronary Risk Evaluation 
algorithm (36).
Venous blood samples were drawn after an overnight fast, 
and assays were performed on fresh plasma samples within 2 h 
of blood collection for standard lipid profile and on unthawed 
serum aliquots for anti-apoA-1 IgG determination, (see below) 
that were immediately processed and stored at −80°C. Standard 
lipid profile was performed by the CHUV Clinical Laboratory 
using a Modular P apparatus (Roche Diagnostics, Switzerland). 
The following analytical procedures (with maximum inter- and 
intra-batch CVs) were used: total cholesterol by the “CHOD-
PAP” method (1.6–1.7%); HDL cholesterol by the “CHOD-PAP/
PEG/Cyclodextrin” method (3.6–0.9%); triglycerides by the 
“GPO-PAP” method (2.9–1.5%); glucose by glucose dehydro-
genase (2.1–1.0%); and serum creatinine by the Jaffe kinetic 
compensated method (2.9–0.7%).
Determination of anti-apoa-1 igg levels
Autoantibodies against apolipoprotein A-1 were measured 
as previously described (19, 22, 37), using the CoLaus study 
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(2003–2006) frozen serum aliquots, stored at −80°C. Maxisorp 
plates (Nunc™, Denmark) were coated with purified, human-
derived delipidated apolipoprotein A-1 (20 µg/ml; 50 µl/well) 
for 1  h at 37°C. After being washed, all wells were blocked 
for 1 h with 2% bovine serum albumin (BSA) in a phosphate 
buffer solution (PBS) at 37°C. Participants’ samples were also 
added to a non-coated well to assess individual non-specific 
binding. After six washing cycles, a 50  µl/well of signal 
antibody (alkaline phosphatase-conjugated anti-human IgG; 
Sigma-Aldrich, St. Louis, MO, USA), diluted 1:1,000 in a 
PBS/BSA 2% solution, was added and incubated for 1  h at 
37°C. After washing six more times, phosphatase substrate 
p-nitrophenyl phosphate disodium (Sigma-Aldrich) dissolved 
in a diethanolamine buffer (pH 9.8) was added and incubated 
for 20 min at 37°C (Molecular Devices™ Versa Max). Optical 
density (OD) was determined at 405 nm, and each sample was 
tested in duplicate. Corresponding non-specific binding was 
subtracted from mean OD for each sample. The specificity of 
detection was assessed using conventional saturation tests by 
Western blot analysis.
As previously described (19, 22, 37), elevated levels of anti-
apoA-1 IgG were set at an OD cut-off of OD >0.64, correspond-
ing to the 97.5th percentile of a reference population of 140 
healthy blood donors. In order to limit the impact of inter-assay 
variation, we further calculated an index consisting in the ratio 
between sample net absorbance and the positive control net 
absorbance × 100. The index value corresponding to the 97.5th 
percentile of the normal distribution was 37. Accordingly, to 
be considered as positive (presenting elevated anti-apoA-1 IgG 
levels), samples had to display both an absorbance value >0.64 
OD and an index value ≥37%.
genome-Wide association study
Genotyping was performed using the Affymetrix GeneChip® 
Human Mapping 500K array set and genotypes were called 
using BRLMM. SNPs with a call rate <70% and individuals with 
call rate <90% were excluded from further analysis. Participants 
found to be of non-European ancestry by principal component 
analysis of the genotype data were also excluded, leaving 5,402 
participants eligible for GWAS. Imputation was performed using 
IMPUTE version 0.2.0 and CEU haplotypes from HapMap 
release 21. The dataset used for imputation consisted in 390,631 
genotyped SNPs with a call rate >0.9, Hardy–Weinberg P-value 
>10−7, and MAF >1%.
Before performing the GWAS, anti-apoA-1 IgG levels were 
adjusted for age, sex, and ancestry principal components. The 
residuals were then inverse normal quantile transformed and 
regressed onto genetic allele dosages. To fine map the genome-
wide significant association at the FCRL2/3 locus, we re-imputed 
the 400-kb window around the top HapMap-associated SNP 
using haplotypes from the HRC reference panel.
study endpoints
The primary study endpoint was overall mortality, but specific 
causes of death were also considered. All deaths and related causes 
were adjudicated by an independent panel of internal medicine 
physicians, blinded to all study variables.
statistics
Statistical analyses were conducted using Stata v14.1 (Stata 
Corp., TX, USA) and MatLab v8.3 (MathWorks, MA, USA). 
Bivariate analysis of continuous variables was performed 
using Student’s or Mann–Whitney test as appropriate, while 
analysis of categorical variables was performed using chi-
square test. The association of anti-apoA-1 IgG levels with 
all-cause mortality was assessed by the log-rank test and by 
Cox proportional hazards regression, adjusting for age, gender, 
hypertension, diabetes, smoking, BMI, eGFR, HDL and low-
density lipoprotein (LDL) cholesterol, baseline CVD, and AD. 
Anti-apoA-1 IgG concentrations were natural log transformed 
to account for skewed distributions, and results were expressed 
as hazard ratios (HRs) and 95% confidence intervals (95% CIs). 
Considering a two-sided alpha of 0.05, our study had 80% 
power to detect a relative risk for all-cause mortality of 1.45 
in participants positive for anti-apoA-1 IgG. All tests were 
two tailed, and P values <0.05 were considered as statistically 
significant.
resUlTs
Figure 1A shows the participants’ selection procedure, and Table 
S1 in Supplementary Material summarizes the baseline charac-
teristics of participants, with or without FU data. Overall, subjects 
lost at FU were more likely to be smokers, hypertensive, obese, 
and with a less favorable lipid profile than subjects included in 
the analysis, but did not differ with regards to anti-apoA-1 IgG 
positivity or serum levels.
During FU, 191 deaths (3.7%) occurred. The three major causes 
of death were cancer, CVD, and infectious diseases. Participants 
who died presented with a significantly higher prevalence of 
anti-apoA-1 IgG positivity (26.7 vs. 19.6%, P  =  0.016) and 
higher anti-apoA-1 IgG levels (median [interquartile range]: 0.43 
[0.30–0.70] vs. 0.39 [0.25–0.59] AU, P = 0.007), than participants 
alive at FU (Table 1). Of note, median anti-apoA-1 IgG values 
of anti-apoA-1 IgG-positive subjects who died at FU were 0.89 
[0.79–1.05] AU.
Kaplan–Meier curves for participants with positive and nega-
tive anti-apoA-1 IgG titers are shown in Figure 1B; participants 
positive for anti-apoA-1 IgG had higher mortality rates than 
participants negative for the marker (4.9 vs. 3.4%, log-rank 
P = 0.034). Conversely, 95.1% of anti-apoA-1 IgG-positive sub-
jects survived, compared to 96.6% of anti-apoA-1 IgG-negative 
subjects corresponding to an absolute survival difference of 1.5% 
between the two groups.
Cox regression analysis indicated that anti-apoA-1 IgG posi-
tivity was associated with a 1.5-fold increased risk of death, and 
this hazard rate remained unchanged after adjustment for the 
aforementioned mortality risk factors, including baseline CVD 
and AD: HR = 1.54 (1.11–2.13), P = 0.01. Similarly, 1 SD increase 
of the log-transformed anti-apoA-1 IgG levels was associated 
with a 15% increase in the risk of all-cause mortality: HR = 1.15 
(1.02–1.28), P = 0.028 (Table 2). Sensitivity analyses excluding 
participants with CVD or AD at baseline led to comparable find-
ings (Table 2).
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FigUre 1 | (a) Participants’ selection procedure. (B) Kaplan–Meier curves for all-cause mortality, according to autoantibodies against apolipoprotein A-1 
(anti-apoA-1 IgG) status. P-value according to log-rank test (P = 0.034).
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TaBle 1 | Baseline characteristics of the sample according to all-cause 
mortality during follow-up.
Overall 
(n = 5,220)
survivors 
(n = 5,029)
non-
survivors 
(n = 191)
P-value
Age, years 52.6 ± 10.7 52.2 ± 10.6 62.7 ± 9.5 <0.001
Male sex, n (%) 2,461 (47.3) 2,337 (46.6) 124 (64.9) <0.001
History of CVD, n (%) 379 (7.3) 337 (6.7) 42 (22.0) <0.001
Current smoking, n (%) 1,356 (26.1) 1,277 (25.5) 79 (41.4) <0.001
Diabetes, n (%) 326 (6.3) 282 (5.6) 44 (23.0) <0.001
BMI (kg/m2) 25.6 ± 4.4 25.6 ± 4.4 26.7 ± 5.5 <0.001
Hypertension, n (%) 1,723 (33.1) 1,613 (32.2) 110 (57.6) <0.001
SBP (mmHg) 127.6 ± 17.7 127.2 ± 17.6 135.3 ± 19.1 <0.001
eGFR (ml/min/1.73 m2) 78.7 ± 15.7 78.8 ± 15.5 75.4 ± 20.0 0.014
Total cholesterol 
(mmol/l)
5.56 ± 1.02 5.57 ± 1.01 5.53 ± 1.19 0.625
HDL cholesterol 
(mmol/l)
1.64 ± 0.44 1.64 ± 0.44 1.54 ± 0.47 0.001
LDL cholesterol (mmol/l) 3.32 ± 0.91 3.32 ± 0.90 3.26 ± 1.02 0.362
Triglycerides (mmol/l) 1.37 ± 1.14 1.36 ± 1.06 1.78 ± 2.33 <0.001
SCORE risk (%) 2.08 ± 3.57 1.91 ± 3.35 6.01 ± 5.80 <0.001
Known AD (RA, SLE) 115 (2.2) 110 (2.2) 5 (2.6) 0.696
Anti-apoA-1 IgG 
positivity
1,035 (19.9) 984 (19.6) 51 (26.7) 0.016
Anti-apoA-1 IgG levels 
(AU)
0.39 [0.34] 0.39 [0.33] 0.43 [0.40] 0.007
Incident overall death 
rate, n (%)
191 (3.7) 191 (3.7)
Cancer-related, n (%) 69 (36.1) 69 (36.1)
CVD-related, n (%) 36 (18.9) 36 (18.9)
Infectious-related, n (%) 25 (13.1) 25 (13.1)
Other causesa, n (%) 51 (26.7) 51 (26.7)
Undetermined, n (%) 10 (5.2) 10 (5.2)
P values are derived from the comparison of patients with low vs. high levels of 
anti-apoA-1 IgG. Variables are expressed as mean ± SD or median [interquartile 
range] as appropriate or number of participants and percentage. Statistical analysis 
for continuous variables was performed by Student’s t-test or Mann–Whitney test 
depending on the normality assumption. Chi-squared test was used for categorical 
variables.
AD, autoimmune disease; CVD, cardiovascular disease; SBP, systolic blood pressure; 
eGFR, estimated glomerular filtration rate according to the MDRD formula; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; RA, rheumatoid arthritis; 
SLE, systemic lupus erythematosus; SCORE, Systematic Coronary Risk Evaluation; 
AU, arbitrary units of optical density; BMI, body mass index; anti-apoA-1 IgG, 
autoantibodies against apolipoprotein A-1.
aOther causes include lung disease (n = 12), bleeding and trauma-related 
complications (n = 11), suicide (n = 9), chronic renal failure (n = 6), non-ischemic heart 
failure (n = 5), chronic liver failure (n = 5), and dementia (n = 3).
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Genome-wide association study on anti-apoA-1 IgG levels 
identified a single locus located in chromosome 1 (157.6–
157.9  Mb) including 21 SNPs significantly associated with 
anti-apoA-1 IgG levels (Figure 2A; Table S2 in Supplementary 
Material). The T allele of the lead SNP (rs6427397) was associ-
ated with an increase of anti-apoA-1 IgG levels by 0.113 AU and 
explained 0.67% of anti-apoA-1 IgG variation. Conversely, in 
logistic regression (yes vs. no anti-apoA-1 IgG positivity) analy-
sis, the T allele of rs6427397 had an odds ratio (OR) of 1.27 (95% 
CI 1.15–1.40) for anti-apoA-1 IgG positivity in our sample. The 
20 remaining SNPs identified in the same region were in strong 
linkage disequilibrium and associated with anti-apoA-1 levels 
at P-value <10−7 (Figure 2B). Most of these SNPs were located 
in or near the Fc receptor-like 2 (FCRL2) and 3 (FCRL3) genes 
and to some extend in the regions spanning the FCRL1 gene 
(Figures 2B,C). SNPs with a previously known biological func-
tion or association with a clinical trait were located in the FCRL3 
gene (Table S2 in Supplementary Material). Additionally, the only 
coding polymorphism among the identified SNPs represents a 
missense variant (rs7522061) also located in the FCRL3 gene. 
We also observed an association between anti-apoA-1 IgG and 
a missense variant (rs1047989) in the human leukocyte antigen 
(HLA)-DQA1 gene, which did not, however, achieve stringent 
genome-wide significance (P = 7.27 × 10−7, data not shown).
DiscUssiOn
This is the first study to demonstrate that anti-apoA-1 IgG levels 
are significantly and independently associated with all-cause 
mortality in the general population. In our population, after 
5 years of FU, 95.1% of anti-apoA-1-positive subjects survived, 
compared to 96.6% of anti-apoA-1-negative participants. This 
corresponds to a modest, nevertheless, significant (P =  0.03) 
absolute survival difference of 1.5% between the two groups.
Our results extend previous findings (19, 22, 25, 26) and sug-
gest that preclinical autoimmunity against apoA-1/HDL—which 
affects up to one-fifth of the general population—may identify 
individuals at increased risk of death. Our findings raise the 
possibility that presence of anti-apoA-1 IgG leads to pathophysi-
ological events affecting not only CV prognosis, but also survival 
in the long term. Based upon previous studies, such events could 
be related to a chronic low-grade inflammatory state through 
sustained activation of the TLR2/TLR4/CD14 complex and 
production of pro-inflammatory cytokines (14, 18, 21, 24, 38), 
associations with elevated high-sensitivity C-reactive protein and 
uric acid levels (23, 25), impairment of HDL function (10–13, 16, 
17), interference with basal heart rate regulation (22, 24, 25) or 
B-cell epitope spreading (39). Other pathophysiological mecha-
nisms, other than those currently ascribed to anti-apoA-1 IgG 
could also be involved, in the same way that multiple molecular 
pathways underlie the associations of other autoantibodies with 
all-cause mortality in the community (7, 9, 40, 41). These chal-
lenging points will have to be investigated in future clinical and 
translational research efforts.
The second notable finding of our study is that anti-apoA-1 
IgG levels are related to genetic polymorphisms belonging or 
regulating the FCRL3 gene. Indeed, our lead SNP (rs6427397) is 
an intergenic variant that represents a strong expression quantita-
tive trait loci for the FCRL3 gene in whole blood (1.2 ×  10−12) 
(42). Additionally, among the 20 remaining FCRL SNPs achieving 
genome-wide significance, the only coding variant identified 
(rs7522061) is a missense variant of the FCRL3 gene.
Fc receptor-like genes are located in the human chromosome 
regions 1q21–23 and belong to the immunoglobulin genes super-
family. FCRL3 in particular is known to encode a mature B-cells 
co-receptor primarily expressed in secondary lymphoid organs 
and involved in B  cell maturation, regulation, and production 
of autoantibodies (43–45). Previous work suggests that FCRL3 
expression further affects T  regulatory cells development and 
function, with high expression resulting in abnormal immune 
activation and breakdown of self-tolerance (46). Corroborating 
TaBle 2 | association between anti-apoa-1 igg and all-cause mortality.
events (n) Unadjusted hr
hr (95% ci)
P-value adjusted hra
hr (95% ci)
P-value
Overall sample (n = 5,220)
 – High vs. low levels
 – For 1 SD increase in log (anti-apoA-1 IgG)
191
191
1.41 (1.02–1.95)
1.14 (1.01–1.28)
0.035
0.040
1.54 (1.11–2.13)
1.15 (1.02–1.30)
0.010
0.028
Participants without CVD at baseline (n = 4,825)
 – High vs. low levels
 – For 1 SD increase in log (anti-apoA-1 IgG)
149
149
1.42 (0.98–2.04)
1.14 (0.99–1.31)
0.062
0.062
1.62 (1.12–2.34)
1.19 (1.03–1.38)
0.011
0.019
Participants without AD at baseline (n = 5,105)
 – High vs. low levels
 – For 1 SD increase in log (anti-apoA-1 IgG)
186
186
1.42 (1.02–1.97)
1.15 (1.01–1.30)
0.036
0.030
1.68 (1.21–2.34)
1.23 (1.07–1.40)
0.002
0.002
Data are expressed as adjusted HRs and 95% CI. Statistical analysis by Cox proportional hazards regression.
AD, autoimmune disease; HR, hazard ratio; CVD, cardiovascular disease; 95% CI, 95% confidence interval; anti-apoA-1 IgG, autoantibodies against apolipoprotein A-1.
aAdjusted for age, sex, hypertension, diabetes, smoking, high- and low-density lipoprotein cholesterol, body mass index, estimated glomerular filtration rate baseline CVD and AD.
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these in vivo findings, large-scale GWAS have identified FCRL3-
related SNPs as major susceptibility genes for numerous ADs in 
humans (44, 47, 48).
The observed association of FRCL3 with anti-apoA-1 IgG 
values in our sample is in line with previous studies showing that 
two-thirds of candidate loci for autoimmunity discovered by 
GWAS represent shared risk factors for multiple ADs (1, 3, 49). 
Among potential pathophysiological mechanisms, FCRL3 may 
predispose to clinical autoimmunity by pleiotropic regulation of 
the production of other deleterious autoantibodies. FCRL3 has 
been associated with the production of cyclic citrullinated pep-
tide autoantibodies in rheumatoid arthritis (RA) (47) and anti-
bodies to thyroid peroxidase in patients suffering from Graves’ 
disease (33). In a study of genetic determinants of autoantibody 
production in over 8,000 type 1 diabetes cases, Plagnol et  al. 
(31) identified the FCRL3 locus to be associated with antibodies 
against insulinoma-associated antigen 2 concluding that FCRL3 
“may have general effects in adaptive immunity, in the complex 
interactions between antigen presenting cells and T cells lead-
ing to antibody producing plasma B  cells.” Unfortunately, we 
were unable to measure in our sample other antibodies, such as 
anti-oxidized LDL, antiphospholipid, antinuclear, or anti-heat 
shock protein antibodies in order to test this hypothesis.
Finally, with regards to anti-apoA-1 IgG and CV disease and 
mortality (19, 20, 22), FCRL3 mRNA levels have been reported 
to be downregulated in patients with myocardial infarction when 
compared to those with stable angina or healthy subjects (50), 
suggesting that FCRL3-mediated immune dysregulation may also 
be involved in atheromatous plaque instability and rupture.
Although statistically significant, the effect of the T allele of 
the lead SNP (rs6427397) on autoantibody levels was modest 
[OR 1.27 (95% CI 1.15–1.40)] and explained 0.67% of total anti-
apoA-1 IgG variation. This is not surprising since incremental 
effect sizes of genetic variants are rather common in genetic stud-
ies of autoimmunity where most risk alleles have ORs less than 
1.2 (29, 30, 32) in spite of their low performance regarding disease 
prediction, these risk variants may provide important etiological 
information based on associated genomic regions, that could 
lead to a more sophisticated understanding of the molecular 
pathways underlying common ADs. Thus, genetic signatures of 
susceptibility to autoimmunity could provide a basis for assess-
ing heterogeneity in disease progression, in response to targeted 
immune-modulating interventions, as well as for rational novel 
drug design.
The fact that the lead SNP in our study relates to an intergenic 
non-coding variant in the FCRL3 locus is in accordance with 
current evidence from high-density genotyping and epigenomic 
studies which demonstrate that in common ADs, up to 90% 
of identified causal variants appear to be non-coding, while 
60% correspond to immune cell enhancers (3). The current 
paradigm supports the notion that intergenic regions are densely 
populated with hundreds of thousands of regulatory elements 
that modulate cell type-specific gene expression (1, 3). In a study 
on RA (47), Kochi et  al. demonstrated that non-coding SNPs 
in the promoter region of FCRL3 have a regulatory effect on 
expression of the FCRL3 gene and relate to augmented autoan-
tibody production in subjects with the susceptible genotype. In 
the same line of thought, our present results indicate that the 
sequence of events leading to high of anti-apoA-1 IgG levels 
could be related to an impaired regulation of gene expres-
sion programs—including FCRL3—a hypothesis that requires 
further study.
Finally, although we did not retrieve any strictly genome-wide 
significant association between anti-apoA-1 IgG and HLA-related 
genes, we did observe an association trend at P = 7.27 × 10−7 that 
may represent a clinically meaningful signal in future studies and 
further relates the presence of these autoantibodies to autoim-
munity susceptibility genes.
Study limitations are worth noting. First, our genetic analysis 
was conducted in a single population sample, including only indi-
viduals of Caucasian ancestry and will require further validation 
in independent cohorts, ideally involving other ethnic groups. 
Since genetic data on anti-apoA-1 IgG are so far inexistent, 
we were unable to identify a replication cohort for our GWAS. 
Nevertheless, our findings represent the first attempt to identify 
the genetic determinants of anti-apoA-1 IgG. Second, as the spe-
cific functionality of T allele of rs6427397 is currently unknown, 
we can only so far extrapolate on the pathophysiological 
FigUre 2 | (a) Manhattan plot of the genome-wide association analysis for autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) levels. The x-axis is 
chromosomal position and the y-axis is the significance (−log P; two-tailed) of association derived by the linear regression. The red line represents genome-wide 
significance level (p = 5 × 10−8) that was achieved by a single locus located in chromosome 1. (B) Regional plot at the Fc receptor-like (FCRL)2/3 locus on 
chromosome 1 showing single-nucleotide polymorphism (SNP) association strength for anti-apoA-1 IgG levels. To fine map the genome-wide significant association 
at the FCRL2/3 locus, we re-imputed the 400-kb window around the top HapMap-associated SNP using haplotypes from the HRC reference panel. −log10 P 
values (y-axis) are presented according to their chromosomal positions (x-axis). The index SNP in the analysis (i.e., SNP with the smallest P-value, rs6427397, 
purple diamond) and the only coding SNP identified (rs7522061) are labeled. The color intensity of each symbol reflects their linkage disequilibrium (r2) values with 
the index SNP, red (r2 > 0.8) through to navy blue (r2 < 0.2). Genes in each region, direction of transcription, and genomic coordinates are shown at the bottom. (c) 
Quantile–quantile plot of SNPs for anti-apoA-1 IgG levels. The negative logarithm of the observed (y-axis) and the expected (x-axis) P-value is plotted for each SNP 
(dot). The black lines indicate the null hypothesis of no true association (x = y) with 95% confidence intervals. Significant deviation from the expected (null) P-value 
distribution is evident only in the upper tail area (blue line), corresponding to SNPs with the strongest association.
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relevance of the reported association, as related to regulation 
of the FCRL3 gene. Indeed, the only genome-wide significant 
coding variant identified (rs7522061) is a missense variant of 
the FCRL3 gene. As we only measured baseline anti-apoA-1 IgG 
levels, we were not able to assess the dynamic of anti-apoA-1 
IgG levels over time in relation with mortality. Knowing whether 
an increase of anti-apoA-1 IgG would precede clinical events or 
whether our findings could be affected by transient anti-apoA-1 
IgG positivity in a single sample will be important to determine 
in future studies.
Similarly, one could argue that since the actual difference in 
anti-apoA-1 IgG levels between the survivors and non-survivors 
was modest, these results are unlikely to be clinically relevant even 
though the relative observed difference in anti-apoA-1 IgG values 
is 9.3% and statistically significant in our sample (P =  0.007), 
as expected from sample power calculation. The fact that the 
distribution of anti-apoA-1 IgG values is positively skewed (25) 
and that low CV risk participants are known to present lower 
levels of anti-apoA-1 IgG than high CV risk subjects (19, 22, 
25) could explain these relatively low anti-apoA-1 IgG values in 
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the general population, despite significant differences between 
survivors and non-survivors. Finally, the observed anti-apoA-1 
IgG values translates in a 19.9% anti-apoA-1 IgG positivity in the 
sample, which is similar to the reported prevalence of other IgG 
autoantibodies in the community (7).
Despite these limitations, our study provides—to our best 
knowledge—the first evidence of a significant association of 
anti-apoA-1 IgG with all-cause mortality and a major AD 
susceptibility gene. Although our findings are in accordance 
and extending previous results, they will need to be replicated 
in independent, adequately powered, prospective cohorts before 
any conclusion on potential clinical implications can be drawn.
cOnclUsiOn
Our study suggests that anti-apoA-1 IgG levels predict all-cause 
mortality in the general population and are associated with a 
single locus involving FCRL3, a gene known to predispose for 
ADs. Our findings indicate that preclinical autoimmunity to 
apoA-1 may identify a substantial proportion of individuals 
at increased risk of death in the general population, a finding 
that will need further validation in independent, prospective 
cohorts.
eThics sTaTeMenT
The study was approved by the Institutional Ethics Committee 
of the University of Lausanne, and written informed consent was 
obtained from all participants before inclusion in the study, in 
accordance with the Declaration of Helsinki.
aUThOr cOnTriBUTiOns
PA and PM-V contributed in study concept and design, analy-
sis, and interpretation of data, statistical analysis and drafting 
of the manuscript, and critical revision of the manuscript 
for important intellectual content. JV, SP, NS, OH, and FM 
contributed in study concept and design, acquisition of the data, 
analysis and interpretation of the data, statistical analysis, and 
critical revision of the manuscript for important intellectual 
content. FM, ZK, GW, PV, and NV had study supervision, 
contributed in study concept and design, acquisition of 
data, analysis and interpretation of data, critical revision of 
the manuscript for important intellectual content, obtained 
funding, and provided study supervision, administrative, and 
technical support. All listed authors gave final approval of the 
manuscript to be published and agreed to be accountable for 
all aspects of the work, ensuring that questions related to the 
accuracy or integrity of any part of the work are appropriately 
investigated and resolved.
acKnOWleDgMenTs
The authors are grateful to Giorgio Pistis for imputation of the 
CoLaus genetic data and Aaron McDaid for performing longevity 
lookup and imputation for their top SNP. The authors express 
their gratitude to all CoLaus study participants and the research 
nurses responsible for recruitment of participants, especially 
Nicole Bonvin. Special gratitude is expressed to Aliki Buhayer 
(Prism Scientific Sàrl) for medical writing support.
FUnDing
This work was supported by the Leenaards Foundation, the 
Faculty of Biology and Medicine of Lausanne, the Swiss 
National Science Foundation (grant numbers 3200B0-105993, 
3200B0-118308, 33CSCO-122661, 33CS30-139468 and 33CS30-
148401, 310030-163335, 31003A-143914) and by the European 
Commission (FP7-INNOVATION I HEALTH-F2-2013-602114; 
Athero-B-Cell: Targeting and Exploiting B Cell Function for 
Treatment in Cardiovascular Disease). Funding sources had no 
involvement in the study design, in the collection, analysis, and 
interpretation of the data, in the writing of the report, or in the 
decision to submit the article for publication.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/fimmu. 
2017.00437/full#supplementary-material.
reFerences
1. Marson A, Housley WJ, Hafler DA. Genetic basis of autoimmunity. J Clin 
Invest (2015) 125(6):2234–41. doi:10.1172/JCI78086 
2. Ramos PS, Shedlock AM, Langefeld CD. Genetics of autoimmune diseases: 
insights from population genetics. J Hum Genet (2015) 60(11):657–64. 
doi:10.1038/jhg.2015.94 
3. Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, et  al. 
Genetic and epigenetic fine mapping of causal autoimmune disease variants. 
Nature (2015) 518(7539):337–43. doi:10.1038/nature13835 
4. Cho JH, Feldman M. Heterogeneity of autoimmune diseases: pathophysi-
ologic insights from genetics and implications for new therapies. Nat Med 
(2015) 21(7):730–8. doi:10.1038/nm.3897 
5. Majka DS, Chang RW. Is preclinical autoimmunity benign? The case of 
cardiovascular disease. Rheum Dis Clin North Am (2014) 40(4):659–68. 
doi:10.1016/j.rdc.2014.07.006 
6. Humphreys JH, Warner A, Chipping J, Marshall T, Lunt M, Symmons DP, 
et  al. Mortality trends in patients with early rheumatoid arthritis over 20 
years: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) 
(2014) 66(9):1296–301. doi:10.1002/acr.22296 
7. Solow EB, Vongpatanasin W, Skaug B, Karp DR, Ayers C, de Lemos JA. 
Antinuclear antibodies are associated with all-cause mortality and car-
diovascular outcomes in the general population. J Am Coll Cardiol (2015) 
65(24):2669–70. doi:10.1016/j.jacc.2015.03.578 
8. Vaarala O, Mänttäri M, Manninen V, Tenkanen L, Puurunen M, Aho K, et al. 
Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective 
cohort of middle-aged men. Circulation (1995) 91(1):23–7. doi:10.1161/ 
01.cir.91.1.23 
9. Ajeganova S, Humphreys JH, Verheul MK, van Steenbergen HW, van Nies 
JAB, Hafström I, et al. Anticitrullinated protein antibodies and rheumatoid 
factor are associated with increased mortality but with different causes 
of death in patients with rheumatoid arthritis: a longitudinal study in 
three European cohorts. Ann Rheum Dis (2016) 75:1924–32. doi:10.1136/
annrheumdis-2015-208579 
10. Ames PR, Matsuura E, Batuca JR, Ciampa A, Lopez LL, Ferrara F, et  al. 
High-density lipoprotein inversely relates to its specific autoantibody favoring 
9Antiochos et al. Anti-ApoA-1 IgG, Mortality and FCRL3 SNPs
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 437
oxidation in thrombotic primary antiphospholipid syndrome. Lupus (2010) 
19(6):711–6. doi:10.1177/0961203309357765 
11. Batuca JR, Ames PR, Amaral M, Favas C, Isenberg DA, Delgado Alves J. Anti-
atherogenic and anti-inflammatory properties of high-density lipoprotein are 
affected by specific antibodies in systemic lupus erythematosus. Rheumatology 
(2009) 48(1):26–31. doi:10.1093/rheumatology/ken397 
12. Batuca JR, Ames PR, Isenberg DA, Alves JD. Antibodies toward high-density 
lipoprotein components inhibit paraoxonase activity in patients with systemic 
lupus erythematosus. Ann N Y Acad Sci (2007) 1108:137–46. doi:10.1196/
annals.1422.016 
13. Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan 
C, et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are 
inversely correlated with paraoxonase activity in systemic lupus erythema-
tosus and primary antiphospholipid syndrome. Arthritis Rheum (2002) 
46(10):2686–94. doi:10.1002/art.10542 
14. Vuilleumier N, Bratt J, Alizadeh R, Jogestrand T, Hafstrom I, Frostegard 
J. Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): 
potential associations with cardiovascular disease and RA disease activity. 
Scand J Rheumatol (2010) 39(6):447–53. doi:10.3109/03009741003742755 
15. Abe H, Tsuboi N, Suzuki S, Sakuraba H, Takanashi H, Tahara K, et al. Anti-
apolipoprotein A-I autoantibody: characterization of monoclonal autoanti-
bodies from patients with systemic lupus erythematosus. J Rheumatol (2001) 
28(5):990–5. 
16. Ahmed MM, Elserougy EM, Al-Gazzar II, Fikry IM, Habib DF, Younes 
KM, et al. Anti-apolipoprotein A-I antibodies and paraoxonase 1 activity in 
systemic lupus erythematosus. EXCLI J (2013) 12:719–32. 
17. Srivastava R, Yu S, Parks BW, Black LL, Kabarowski JH. Autoimmune-
mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 
1 activity in systemic lupus erythematosus-prone gld mice. Arthritis Rheum 
(2011) 63(1):201–11. doi:10.1002/art.27764 
18. Montecucco F, Braunersreuther V, Burger F, Lenglet S, Pelli G, Carbone F, 
et  al. Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque 
vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4. 
Thromb Haemost (2015) 114:410–22. doi:10.1160/th14-12-1039 
19. Montecucco F, Vuilleumier N, Pagano S, Lenglet S, Bertolotto M, 
Braunersreuther V, et  al. Anti-apolipoprotein A-1 auto-antibodies are 
active mediators of atherosclerotic plaque vulnerability. Eur Heart J (2011) 
32(4):412–21. doi:10.1093/eurheartj/ehq521 
20. Pagano S, Carbone F, Burger F, Roth A, Bertolotto M, Pane B, et  al. Anti-
apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis. 
Thromb Haemost (2016) 116(3):554–64. doi:10.1160/TH16-03-0229 
21. Pagano S, Satta N, Werling D, Offord V, de Moerloose P, Charbonney E, 
et  al. Anti-apolipoprotein A-1 IgG in patients with myocardial infarction 
promotes inflammation through TLR2/CD14 complex. J Intern Med (2012) 
272(4):344–57. doi:10.1111/j.1365-2796.2012.02530.x 
22. Vuilleumier N, Rossier MF, Pagano S, Python M, Charbonney E, Nkoulou R, 
et  al. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prog-
nostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 
(2010) 31(7):815–23. doi:10.1093/eurheartj/ehq055 
23. de Seny D, Cobraiville G, Charlier E, Neuville S, Lutteri L, Le Goff C, et al. 
Apolipoprotein-A1 as a damage-associated molecular patterns protein in 
osteoarthritis: ex vivo and in  vitro pro-inflammatory properties. PLoS One 
(2015) 10(4):e0122904. doi:10.1371/journal.pone.0122904 
24. Mannic T, Satta N, Pagano S, Virzi J, Python M, Montecucco F, et al. CD14 
as a potential receptor and key regulator of anti-apolipoproteina-1 IgG-
mediated positive chronotropic effect on cardiac cells. Atherosclerosis (2015) 
241(1):e6–7. doi:10.1016/j.atherosclerosis.2015.04.040 
25. Antiochos P, Marques-Vidal P, Virzi J, Pagano S, Satta N, Bastardot F, et al. 
Association between anti-apolipoprotein A-1 antibodies and cardiovascular 
disease in the general population. Results from the CoLaus study. Thromb 
Haemost (2016) 116(4):764–71. doi:10.1160/TH16-03-0248 
26. Chistiakov DA, Orekhov AN, Bobryshev YV. ApoA1 and ApoA1-specific 
self-antibodies in cardiovascular disease. Lab Invest (2016) 96(7):708–18. 
doi:10.1038/labinvest.2016.56 
27. Batuca JR, Amaral MC, Favas C, Paula FS, Ames PR, Papoila AL, et  al. 
Extended-release niacin increases anti-apolipoprotein A-I antibodies 
that block the antioxidant effect of high-density lipoprotein-cholesterol: 
the EXPLORE clinical trial. Br J Clin Pharmacol (2016). doi:10.1111/ 
bcp.13198 
28. Radwan MM, El-Lebedy D, Fouda R, Elsorougy E. Anti-apolipoprotein A-1 
antibodies and carotid intima-media thickness in Egyptian women with sys-
temic lupus erythematosus. Clin Rheumatol (2014) 33(4):493–8. doi:10.1007/
s10067-013-2399-8 
29. Armstrong DL, Zidovetzki R, Alarcon-Riquelme ME, Tsao BP, Criswell 
LA, Kimberly RP, et al. GWAS identifies novel SLE susceptibility genes and 
explains the association of the HLA region. Genes Immun (2014) 15(6):347–54. 
doi:10.1038/gene.2014.23 
30. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, 
et  al. Genome-wide association study meta-analysis identifies seven new 
rheumatoid arthritis risk loci. Nat Genet (2010) 42(6):508–14. doi:10.1038/ 
ng.582 
31. Plagnol V, Howson JMM, Smyth DJ, Walker N, Hafler JP, Wallace C, et  al. 
Genome-wide association analysis of autoantibody positivity in type 1 
diabetes cases. PLoS Genet (2011) 7(8):e1002216. doi:10.1371/journal.pgen. 
1002216 
32. Chung SA, Taylor KE, Graham RR, Nititham J, Lee AT, Ortmann WA, et al. 
Differential genetic associations for systemic lupus erythematosus based on 
anti-dsDNA autoantibody production. PLoS Genet (2011) 7(3):e1001323. 
doi:10.1371/journal.pgen.1001323 
33. Wellcome Trust Case Control Consortium, Australo-Anglo-American 
Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, 
Craddock N, et al. Association scan of 14,500 nonsynonymous SNPs in four 
diseases identifies autoimmunity variants. Nat Genet (2007) 39(11):1329–37. 
doi:10.1038/ng.2007.17 
34. Kurreeman F, Liao K, Chibnik L, Hickey B, Stahl E, Gainer V, et al. Genetic 
basis of autoantibody positive and negative rheumatoid arthritis risk in a 
multi-ethnic cohort derived from electronic health records. Am J Hum Genet 
(2011) 88(1):57–69. doi:10.1016/j.ajhg.2010.12.007 
35. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D, et al. The 
CoLaus study: a population-based study to investigate the epidemiology and 
genetic determinants of cardiovascular risk factors and metabolic syndrome. 
BMC Cardiovasc Disord (2008) 8:6. doi:10.1186/1471-2261-8-6 
36. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 
European Guidelines on cardiovascular disease prevention in clinical practice: 
The Sixth Joint Task Force of the European Society of Cardiology and Other 
Societies on Cardiovascular Disease Prevention in Clinical Practice (con-
stituted by representatives of 10 societies and by invited experts) developed 
with the special contribution of the European Association for Cardiovascular 
Prevention & Rehabilitation (EACPR). Eur Heart J (2016) 37(29):2315–81. 
doi:10.1093/eurheartj/ehw106 
37. Vuilleumier N, Bas S, Pagano S, Montecucco F, Guerne PA, Finckh A, 
et  al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in 
patients with rheumatoid arthritis. Arthritis Rheum (2010) 62(9):2640–50. 
doi:10.1002/art.27546 
38. Rasheed H, Phipps-Green AJ, Topless R, Smith MD, Hill C, Lester S, et al. 
Replication of association of the apolipoprotein A1-C3-A4 gene cluster 
with the risk of gout. Rheumatology (2016) 55(8):1421–30. doi:10.1093/
rheumatology/kew057 
39. Cornaby C, Gibbons L, Mayhew V, Sloan CS, Welling A, Poole BD. B  cell 
epitope spreading: mechanisms and contribution to autoimmune diseases. 
Immunol Lett (2015) 163(1):56–68. doi:10.1016/j.imlet.2014.11.001 
40. Metzger M-H, Heier M, Mäki M, Bravi E, Schneider A, Löwel H, et al. Mortality 
excess in individuals with elevated IgA anti-transglutaminase antibodies: the 
KORA/MONICA Augsburg Cohort Study 1989-1998. Eur J Epidemiol (2006) 
21(5):359–65. doi:10.1007/s10654-006-9002-4 
41. Endler G, Marsik C, Jilma B, Schickbauer T, Vormittag R, Wagner O, et al. 
Anti-cardiolipin antibodies and overall survival in a large cohort: prelim-
inary report. Clin Chem (2006) 52(6):1040–4. doi:10.1373/clinchem.2005. 
063925 
42. GTExPortal. (2017). Available from: http://www.gtexportal.org/
43. Gibson AW, Li FJ, Wu J, Edberg JC, Su K, Cafardi J, et al. The FCRL3-169CT 
promoter single-nucleotide polymorphism, which is associated with systemic 
lupus erythematosus in a Japanese population, predicts expression of receptor 
protein on CD19+ B cells. Arthritis Rheum (2009) 60(11):3510–2. doi:10.1002/
art.24915 
44. Yang Y, Su X, Zhang K, Zhou R. The Fc receptor-like 3 gene polymorphisms 
and susceptibility to autoimmune diseases: an updated meta-analysis. 
Autoimmunity (2013) 46(8):547–58. doi:10.3109/08916934.2013.835804 
10
Antiochos et al. Anti-ApoA-1 IgG, Mortality and FCRL3 SNPs
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 437
45. Kochi Y, Myouzen K, Yamada R, Suzuki A, Kurosaki T, Nakamura Y, et al. 
FCRL3, an autoimmune susceptibility gene, has inhibitory potential on B-cell 
receptor-mediated signaling. J Immunol (2009) 183(9):5502–10. doi:10.4049/
jimmunol.0901982 
46. Swainson LA, Mold JE, Bajpai UD, McCune JM. Expression of the autoim-
mune susceptibility gene FcRL3 on human regulatory T  cells is associated 
with dysfunction and high levels of PD-1. J Immunol (2010) 184(7):3639–47. 
doi:10.4049/jimmunol.0903943 
47. Kochi Y, Yamada R, Suzuki A, Harley JB, Shirasawa S, Sawada T, et  al. A 
functional variant in FCRL3, encoding Fc receptor-like 3, is associated 
with rheumatoid arthritis and several autoimmunities. Nat Genet (2005) 
37(5):478–85. doi:10.1038/ng1540 
48. Bajpai UD, Swainson LA, Mold JE, Graf JD, Imboden JB, McCune JM. A func-
tional variant in FCRL3 is associated with higher Fc receptor-like 3 expression 
on T cell subsets and rheumatoid arthritis disease activity. Arthritis Rheum 
(2012) 64(8):2451–9. doi:10.1002/art.34457 
49. Cotsapas C, Hafler DA. Immune-mediated disease genetics: the shared basis of 
pathogenesis. Trends Immunol (2013) 34(1):22–6. doi:10.1016/j.it.2012.09.001 
50. Yan W, Song H, Jiang J, Xu W, Gong Z, Duan Q, et  al. Characteristics of 
B cell-associated gene expression in patients with coronary artery disease. Mol 
Med Rep (2016) 13(5):4113–21. doi:10.3892/mmr.2016.5029 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Antiochos, Marques-Vidal, Virzi, Pagano, Satta, Hartley, 
Montecucco, Mach, Kutalik, Waeber, Vollenweider and Vuilleumier. This is an 
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these terms.
